Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug
Sponsor: GeneCradle Inc
Summary
This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease. Patients diagnosed with late-onset Pompe disease (LOPD) who are ≥ 6 years old will be studied.
Official title: A Multi-centered, Single Arm, Open Labeled, Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector Expressing the Human Acid Alpha-glucosidase (GAA) Transgene Intravenous Injection in Patients With Late-onset Pompe Disease
Key Details
Gender
All
Age Range
6 Years - Any
Study Type
INTERVENTIONAL
Enrollment
33
Start Date
2024-04-19
Completion Date
2026-12
Last Updated
2025-07-03
Healthy Volunteers
No
Conditions
Interventions
GC301
GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
Locations (1)
Chinese PLA General Hospital
Beijing, China